Microporous Zirconium Silicate Particle-Size Control for Hyperkalemia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing microporous zirconium silicate compositions used for treating hyperkalemia cause adverse effects such as mixed leukocyte inflammation, acute urinary bladder inflammation, and increased urine pH, with issues of crystalline impurities and low cation exchange capacity.
Innovation Solution
Development of novel microporous zirconium silicate compositions with optimized particle size distribution, enhanced cation exchange capacity, and reduced sodium content, formulated for oral administration to effectively reduce serum potassium levels without causing undesirable side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If microporous zirconium silicate compositions are used to remove potassium ions from the gastrointestinal tract, then the potassium exchange capacity is improved, but adverse effects such as mixed leukocyte inflammation, acute urinary bladder inflammation, and increased urine pH occur
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution of microporous zirconium silicate to a specific range (median diameter 4-20 micrometers, with controlled percentages in different size ranges). This parameter optimization maintains high potassium exchange capacity while reducing adverse effects such as inflammation and urine pH increase, thereby resolving the technical contradiction between efficacy and safety
Solution Approach 2:
The patent uses composite material formulation by combining microporous zirconium silicate with specific excipients and additives in defined proportions. This composite approach enhances the therapeutic effect of potassium removal while mitigating harmful side effects, addressing the contradiction between high potassium exchange capacity and reduction of adverse reactions
2Quantity of substance
If existing microporous zirconium silicate compositions are administered, then potassium removal efficacy is achieved, but crystalline impurities and low cation exchange capacity are present
Solution Approach 1:
The patent applies parameter changes by precisely controlling the particle size distribution parameters of microporous zirconium silicate, specifying that particles with diameter less than 3 micrometers should constitute less than 10% by weight, and particles between 3-20 micrometers should constitute more than 80% by weight. This parameter control reduces crystalline impurities and enhances cation exchange capacity while maintaining potassium removal efficacy
Solution Approach 2:
The patent employs fluidization technology during the manufacturing process to improve particle uniformity and reduce crystalline impurities. By using fluidized bed processing, the method achieves better control over particle size distribution and reduces unwanted crystalline phases, thereby improving manufacturing precision without compromising therapeutic effect
3Quantity of substance
If microporous zirconium silicate is used to treat hyperkalemia, then serum potassium levels are reduced, but particles may enter the bloodstream and sodium is released into the blood
Solution Approach 1:
The patent applies parameter changes by optimizing the particle size distribution to have a median diameter of 4-20 micrometers, with specific control over the percentage of fine particles. This parameter optimization prevents particle entry into the bloodstream while maintaining effective potassium adsorption capacity, thereby resolving the contradiction between therapeutic efficacy and safety concerns
Solution Approach 2:
The patent employs a disposable oral administration formulation where the microporous zirconium silicate is contained in a controlled-release matrix. This approach ensures that the material remains in the gastrointestinal tract for controlled action and is subsequently excreted, preventing entry into the bloodstream and minimizing sodium release systemic effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel compositions significantly decrease and sustain normal serum potassium levels in patients with hyperkalemia, minimizing adverse reactions and maintaining therapeutic efficacy over an extended period.
Implementation Method 1
microporous zirconium silicate compositions that are specifically formulated at particular dosages to remove select toxins, e.g., potassium ions or ammonium ions, from the gastrointestinal tract
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.